Elizabeth A David1, Megan E Daly2, Chin-Shang Li3, Chi-Lu Chiu4, David T Cooke5, Lisa M Brown5, Joy Melnikow6, Karen Kelly7, Robert J Canter8. 1. Section of General Thoracic Surgery and Outcomes Research Group, Department of Surgery, University of California Davis Medical Center, Sacramento, California; Heart Lung Vascular Center, David Grant Medical Center, Travis Air Force Base, California. Electronic address: Eadavid@ucdavis.edu. 2. Department of Radiation Oncology, University of California Davis Medical Center, Sacramento, California. 3. Department of Public Health Sciences, University of California Davis School of Medicine, Davis, California. 4. Department of Statistics, University of California Davis, Davis, California. 5. Section of General Thoracic Surgery and Outcomes Research Group, Department of Surgery, University of California Davis Medical Center, Sacramento, California. 6. Center for Healthcare Policy and Research, University of California Davis, Sacramento, California. 7. Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California. 8. Division of Surgical Oncology and Outcomes Research Group, Department of Surgery, University of California Davis Medical Center, Sacramento, California.
Abstract
INTRODUCTION: Variation in treatment and survival outcomes for NSCLC is high among patients with stage III or IV disease, but patients with untreated NSCLC have not been critically analyzed to evaluate for improvable outcomes. We evaluated treatment trends and their association with oncologic outcomes for NSCLC, hypothesizing that there are a substantial number of untreated patients who are similar to patients who undergo treatment. METHODS: Linear regression was used to calculate trends in utilization of treatment. Kaplan-Meier and Cox regression modeling were used to determine predictors of receiving treatment. Propensity matching was used to compare survival among subsets of treated versus untreated patients. RESULTS: Patients with primary NSCLC were identified from the National Cancer Data base from 1998 to 2012, and 21% of patients (190,539) received no treatment. For stage IIIA and IV, the proportion of untreated patients increased over the study period by 0.21% and 0.4%, respectively (p = 0.003 and p < 0.0001). Regardless of stage, untreated patients had significantly shorter overall survival (OS) (p < 0.0001). Propensity-matched analyses of 6144 stage IIIA patient pairs treated with chemoradiation versus no treatment confirmed shorter OS for untreated patients (median 16.5 versus 6.1 months, p < 0.0001). For 19,046 stage IV patient pairs treated with chemotherapy versus no treatment, similar results were obtained (median OS 9.3 versus 2.0 months, p < 0.0001). CONCLUSIONS: The proportion of untreated patients with stage IIIA and IV disease is increasing. Survival outcomes among patients with advanced-stage disease are superior with treatment, independent of selection bias. The benefits and risks of treatment should be carefully assessed before choosing to forego treatment. Published by Elsevier Inc.
INTRODUCTION: Variation in treatment and survival outcomes for NSCLC is high among patients with stage III or IV disease, but patients with untreated NSCLC have not been critically analyzed to evaluate for improvable outcomes. We evaluated treatment trends and their association with oncologic outcomes for NSCLC, hypothesizing that there are a substantial number of untreated patients who are similar to patients who undergo treatment. METHODS: Linear regression was used to calculate trends in utilization of treatment. Kaplan-Meier and Cox regression modeling were used to determine predictors of receiving treatment. Propensity matching was used to compare survival among subsets of treated versus untreated patients. RESULTS:Patients with primary NSCLC were identified from the National Cancer Data base from 1998 to 2012, and 21% of patients (190,539) received no treatment. For stage IIIA and IV, the proportion of untreated patients increased over the study period by 0.21% and 0.4%, respectively (p = 0.003 and p < 0.0001). Regardless of stage, untreated patients had significantly shorter overall survival (OS) (p < 0.0001). Propensity-matched analyses of 6144 stage IIIA patient pairs treated with chemoradiation versus no treatment confirmed shorter OS for untreated patients (median 16.5 versus 6.1 months, p < 0.0001). For 19,046 stage IV patient pairs treated with chemotherapy versus no treatment, similar results were obtained (median OS 9.3 versus 2.0 months, p < 0.0001). CONCLUSIONS: The proportion of untreated patients with stage IIIA and IV disease is increasing. Survival outcomes among patients with advanced-stage disease are superior with treatment, independent of selection bias. The benefits and risks of treatment should be carefully assessed before choosing to forego treatment. Published by Elsevier Inc.
Authors: Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps Journal: Chest Date: 2005-07 Impact factor: 9.410
Authors: Alexander C Small; Che-Kai Tsao; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; James H Godbold; Cardinale B Smith; Guru Sonpavde; William K Oh; Matthew D Galsky Journal: Cancer Date: 2012-06-15 Impact factor: 6.860
Authors: Timothy R Wassenaar; Jens C Eickhoff; Daniel R Jarzemsky; Stevens S Smith; Marilyn L Larson; Joan H Schiller Journal: J Thorac Oncol Date: 2007-08 Impact factor: 15.609
Authors: Bernardo H L Goulart; Carolina M Reyes; Catherine R Fedorenko; David G Mummy; Sacha Satram-Hoang; Lisel M Koepl; David K Blough; Scott D Ramsey Journal: J Oncol Pract Date: 2013-01 Impact factor: 3.840
Authors: Ronica H Nanda; Yuan Liu; Theresa W Gillespie; John L Mikell; Suresh S Ramalingam; Felix G Fernandez; Walter J Curran; Joseph Lipscomb; Kristin A Higgins Journal: Cancer Date: 2015-09-08 Impact factor: 6.860
Authors: Dan J Raz; Jason A Zell; S-H Ignatius Ou; David R Gandara; Hoda Anton-Culver; David M Jablons Journal: Chest Date: 2007-05-15 Impact factor: 9.410
Authors: Heidi A Hamann; Elizabeth S Ver Hoeve; Lisa Carter-Harris; Jamie L Studts; Jamie S Ostroff Journal: J Thorac Oncol Date: 2018-05-23 Impact factor: 15.609
Authors: Frances B Maguire; Cyllene R Morris; Arti Parikh-Patel; Rosemary D Cress; Theresa H M Keegan; Chin-Shang Li; Patrick S Lin; Kenneth W Kizer Journal: JNCI Cancer Spectr Date: 2019-04-04